For instance, Ye et al. reported that SLC14A1 is markedly downregulated in prostate cancer, and patients with high SLC14A1 expression have a longer biochemical recurrence-free period, indicating that SLC14A1 may exert an anti-cancer effect in the prostate and is mediated through specific miRNAs and B lymphocyte infiltration [33]. This evidence concerns the gene SLC14A1 and prostate carcinoma.